Skip to content
GLP-1 Decoder

South Carolina Medicaid GLP-1 Coverage: Wegovy, Zepbound

Not for weight loss. South Carolina Medicaid covers GLP-1s only for type 2 diabetes and other approved uses. South Carolina Medicaid stopped covering GLP-1s for weight loss in January 2026, a year after adding it. Diabetes use stays covered.

For weight loss
Ended January 2026
For type 2 diabetes
Covered
Weight loss, KFF survey January 2026
Not covered

Does South Carolina Medicaid cover GLP-1s?

Sources: KFF.

Each drug on its own: Wegovy, Zepbound, Ozempic, Mounjaro

GLP-1 drugs in South Carolina Medicaid
MedicineMain useIn South Carolina MedicaidEvery state
WegovyWeight lossEnded January 2026Wegovy and Medicaid
ZepboundWeight lossEnded January 2026Zepbound and Medicaid
FoundayoWeight lossEnded January 2026Not listed
SaxendaWeight lossEnded January 2026Saxenda and Medicaid
OzempicType 2 diabetesCovered for type 2 diabetesOzempic and Medicaid
MounjaroType 2 diabetesCovered for type 2 diabetesMounjaro and Medicaid
RybelsusType 2 diabetesCovered for type 2 diabetesRybelsus and Medicaid
TrulicityType 2 diabetesCovered for type 2 diabetesTrulicity and Medicaid
VictozaType 2 diabetesCovered for type 2 diabetesVictoza and Medicaid

Sources: KFF.

Rules covering prior authorization

Source: KFF.

How to check your plan

  1. Look up the drug on the state's list: South Carolina Medicaid drug list.
  2. If your Medicaid is managed by a managed care plan, call the number on your member card. Ask if prior authorization is needed for the drug.
  3. Ask your prescriber which GLP-1 is preferred. Drugs that are preferred receive approval faster.
  4. Keep the approval or denial notice. It tells you which rule applies.

Which brand pages matter in South Carolina?

Upon a denial from South Carolina Medicaid

If coverage says no
MedicineLowest self-payManufacturer offer if your plan does not cover it
Wegovy$149 a monthNot listed
Zepbound$299 a month$299 a month
Foundayo$149 a monthNot listed

Sources: foundayo.lilly.com, TrumpRx, NovoCare, CMS.